Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effect of Sodium Glucose Transporter 2 Inhibitor Empagliflozin on Proteinuria and Kidney Disease Progression in Patients With Non-diabetic Glomerulonephritis- A Randomized Controlled Trial

NCT05283057 is registered in ClinicalTrials.gov with Kasr El Aini Hospital as lead sponsor.

NCT NCT05283057
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05283057 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effect of Sodium Glucose Transporter 2 Inhibitor Empagliflozin on Proteinuria and Kidney Disease Progression in Patients With Non-diabetic Glomerulonephritis- A Randomized Controlled Trial
Lead sponsor
Kasr El Aini Hospital
Phase
Phase 3
Overall status
Completed
Start date
February 20, 2020
Completion date
September 30, 2021
Enrollment
50 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

glomerulonephritis, proteinuria